Trials / Completed
CompletedNCT02595281
HE4 as a Relapse Biomarker in Ovarian Cancers
Determination of the Interest of HE4 as a Relapse Biomarker in Ovarian Cancers Stages IIIb, IIIc and IV After Neo-adjuvant Chemotherapy and Surgery.
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Institut de Cancérologie de Lorraine · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
HE4 is a more sensitive marker than CA-125 in patients with ovarian cancers. The interest of serum HE4 before surgery has been demonstrated to predict overall survival and its interest has also been shown in combination with CA-125 (ROMA algorithm) to identify high risk patients. To date, no study shows clearly the predictive potential of serum HE4 as an early relapse biomarker in ovarian cancers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Experimental arm | Serum samples are collected: * at each neoadjuvant chemotherapy cycle * before surgery * at each adjuvant chemotherapy cycle * at each injection of bevacizumab as maintenance therapy * stop at the progression or after 24 months post chemotherapy |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2022-07-18
- Completion
- 2022-07-18
- First posted
- 2015-11-03
- Last updated
- 2022-12-19
Locations
7 sites across 1 country: France
Source: ClinicalTrials.gov record NCT02595281. Inclusion in this directory is not an endorsement.